Agilent Technologies has launched Agilent Advanced Therapeutics, a unified contract development and manufacturing organization (CDMO) platform designed to integrate the company’s expanding manufacturing capabilities across the United States and Canada. The initiative brings together expertise in oligonucleotides, microbial fermentation, complex
Agilent Technologies has entered into a definitive agreement to acquire Biocare Medical from an investor group led by Excellere Partners and GHO Capital Partners LLP in an all-cash transaction valued at $950 million. The deal is expected to close by
GelMEDIX has announced a global partnership with Catalent to support the development and clinical manufacturing of induced pluripotent stem cell (iPSC)-derived therapies for ocular and retinal diseases. The collaboration will enable GelMEDIX to access Catalent’s GMP-compliant iPSC lines and manufacturing
Chiesi Group has expanded its collaboration with Bespak to increase manufacturing capacity for pressurized metered dose inhalers (pMDIs) at Bespak’s Holmes Chapel facility in the United Kingdom. The agreement supports the next phase of Chiesi’s Carbon Minimal Inhaler (CMI) program,
PharmaResearch, headquartered in Seongnam, South Korea, has received clearance from the U.S. Food and Drug Administration for its Investigational New Drug (IND) application to initiate a Phase 1 clinical trial of PRD-101, a nano-based anticancer drug candidate. The authorization allows
Cellistic has appointed Jason Conner as Chief Executive Officer, effective immediately. Conner will also assume the same role at Ncardia, Cellistic’s sister company focused on stem cell–based solutions for drug discovery and safety assessment. He has served on the Board
Polyrizon announced the successful production of a Good Manufacturing Practice (GMP) batch of clinical trial material (CTM) for its lead product candidate. The company is a pre-clinical-stage biotechnology firm developing intranasal administered solutions. The GMP batch was manufactured in collaboration
mAbxience has selected the Genedata Bioprocess enterprise platform to structure and harmonize bioprocess development data across its operations. The company operates as a contract development and manufacturing organization (CDMO) focused on biosimilars and is majority-owned by the Fresenius Kabi group.
Andelyn Biosciences has announced the launch of The Andelyn Foundation, a nonprofit organization created to support families living with rare and ultra-rare diseases through awareness initiatives, fundraising activities, and community engagement. The company operates as a CDMO providing cell and
Samsung Biologics has entered a collaboration agreement with Eli Lilly and Company to establish a Lilly Gateway Labs (LGL) site in Korea. The facility will support early-stage and emerging biotechnology companies as they advance scientific research toward development and manufacturing.
